Recent Posts
News•Feb 26, 2026
Bristol Myers Says ADC Licensed From China Hits Mark in Aggressive Breast Cancer
Bristol Myers Squibb reported that its antibody‑drug conjugate iza‑bren, licensed from Chinese partner SystImmune, achieved statistically significant improvements in progression‑free and overall survival versus chemotherapy in a Phase III trial for advanced triple‑negative breast cancer. The study, conducted in mainland China and sponsored by Sichuan Biokin, underscores the drug’s dual EGFR/HER3 targeting strategy. The partnership could be valued at more than $8 billion, positioning the ADC as a cornerstone of BMS’s pipeline renewal. Success in China also highlights the country’s growing importance for global biotech development.
By BioPharma Dive
News•Feb 25, 2026
Alkermes’ Richard Pops to Step Down After Three-Decade Run as CEO
Richard Pops will step down as Alkermes CEO on July 31 after a 32‑year tenure, remaining as board chair. COO Blair Jackson will succeed him and join the board during the transition. Under Pops, Alkermes shifted from drug‑delivery to commercial...
By BioPharma Dive
News•Feb 18, 2026
Lilly to Pay CSL $100M to License Monoclonal Antibody Targeting IL-6
Eli Lilly has agreed to pay CSL Ltd. $100 million to license the monoclonal antibody clazakizumab, which targets interleukin‑6. Under the agreement, CSL will keep development rights for the drug’s use in preventing cardiovascular complications in end‑stage kidney disease patients, currently...
By BioPharma Dive
News•Feb 18, 2026
FDA Accepts BMS Protein Degrader for Review; Disc Rare Disease Drug Rejected
The FDA has accepted Bristol Myers Squibb’s protein‑degrading multiple myeloma candidate iberdomide for review, with a decision expected by Aug. 17 after a Phase 3 trial showed higher minimal residual disease‑negative rates. In contrast, the agency rejected Disc Medicine’s accelerated‑approval bid for...
By BioPharma Dive
News•Feb 17, 2026
Selecting the Optimal Cell Therapy Manufacturing Platform
Developers of cell and gene therapies must choose between fully integrated turnkey platforms and modular, multi‑device systems. Integrated solutions deliver rapid time‑to‑value and simplified workflows, ideal for low‑volume autologous products, but they restrict reagent flexibility and scale. Modular platforms provide...
By BioPharma Dive
News•Feb 17, 2026
How to Evaluate Prospective Diagnostic Laboratory Partners for Your Patient Support Program
The pharmaceutical industry now invests over $5 billion annually in patient support programs (PSPs), which boost adherence by roughly 30 % and lower overall healthcare costs. Diagnostic laboratory testing is a cornerstone of these programs, delivering timely data that guides dosing, monitors...
By BioPharma Dive
News•Feb 12, 2026
Seres to Lay Off Staff, Pause Top Program in Latest Reboot
Seres Therapeutics, a cash‑strapped microbiome drug developer, will cut about 30 % of its workforce and suspend its lead program SER‑155, which targets graft‑versus‑host disease. The company will redirect resources toward earlier‑stage immunology candidates such as SER‑603, aiming to extend its...
By BioPharma Dive
News•Feb 11, 2026
Gilead Dips as ‘Strong’ Earnings Outweighed by High Expectations for New HIV Drug
Gilead Sciences reported a strong fourth‑quarter, with product sales reaching $7.9 billion, a 5% year‑over‑year increase, and its flagship HIV treatments Biktarvy and Descovy surpassing analyst forecasts. The company projected full‑year sales of $29.6‑$30 billion and EPS of $8.45‑$8.85, staying within consensus...
By BioPharma Dive
News•Feb 9, 2026
Takeda, Iambic Partner in Latest Pharma AI Push
Japan’s largest drugmaker Takeda has signed a multiyear agreement with AI specialist Iambic Therapeutics, potentially worth more than $1.7 billion. The partnership grants Takeda access to Iambic’s AI‑driven drug discovery platform and a protein‑receptor interaction model, targeting small‑molecule treatments for cancer,...
By BioPharma Dive
News•Feb 9, 2026
Hengrui, Kailera Tout Positive Results for Dual-Acting Obesity Pill
Hengrui Pharma and Kailera Therapeutics reported Phase 2 results for oral ribupatide, a dual GLP‑1/GIP obesity pill. In a 166‑patient, 26‑week study the drug produced an average 12 % weight loss versus 2 % for placebo, with over half of high‑dose participants shedding...
By BioPharma Dive
News•Feb 9, 2026
Navigating the Complexities of Cell and Gene Therapy Supply Chains
Cell and gene therapies (CGTs) promise breakthrough treatments but demand highly complex supply chains. The process spans cell collection, manufacturing, temperature‑controlled transport, and delivery, requiring strict regulatory compliance and real‑time data integrity. Developers face challenges such as cold‑chain logistics, stakeholder...
By BioPharma Dive
News•Feb 6, 2026
White House’s Online Service for Drug Sales Debuts with Limited Impact on Prices
The White House launched TrumpRx, an online portal selling about 40 prescription drugs from manufacturers such as Pfizer, Eli Lilly, and Novo Nordisk at discounted rates. The platform targets cash‑pay consumers, offering "most‑favored‑nation" pricing that mirrors low overseas prices. While the service...
By BioPharma Dive
News•Feb 2, 2026
Novo Combination Obesity Shot Meets Goal in Diabetes Trial
Novo Nordisk announced Phase 3 results for its combination injection CagriSema, showing superior glycemic control and greater weight loss than Wegovy in patients with type 2 diabetes and obesity. In the 68‑week trial of more than 2,700 participants, CagriSema lowered HbA1c by...
By BioPharma Dive
Deals•Feb 2, 2026
Wave Life Sciences Reacquires Global Rights to RNA Editing Drug WVE-006 From GSK
Wave Life Sciences announced it has reached a deal with GSK to reclaim global rights to its RNA editing therapy WVE-006 for alpha‑1 antitrypsin deficiency, ending GSK’s involvement in the program. The rights transfer follows a 2022 collaboration and is...
BioPharma Dive
News•Jan 30, 2026
Amgen Gives up on Its Once-Prized Eczema Drug
Amgen has terminated its collaboration with Kyowa Kirin on the OX40‑targeting eczema drug rocatinlimab, returning all rights to the Japanese partner. The decision follows Phase 3 trials that met primary endpoints but failed to demonstrate superiority over established therapy Dupixent and showed...
By BioPharma Dive
News•Jan 30, 2026
Politicization Runs Deeper than Ever at FDA, Risking Long-Term Impacts
The FDA has undergone an unprecedented wave of politicization in the past year, marked by mass staff departures, early retirements, and a surge of political appointees across senior roles. This shift has altered advisory committees, review processes, and introduced the...
By BioPharma Dive
Deals•Jan 28, 2026
Halozyme Therapeutics Acquires Surf Bio for up to $400M
Halozyme Therapeutics announced the acquisition of privately held drug delivery specialist Surf Bio. The deal includes an upfront payment of $300 million with potential earn‑out bringing total consideration to $400 million. The acquisition aims to expand Halozyme’s platform for high‑concentration...
BioPharma Dive
Deals•Jan 26, 2026
Helix Acquisition Corp. III, Backed by Cormorant, Raises $150M in IPO
Biotech investor Cormorant Asset Management launched Helix Acquisition Corp. III, a SPAC that raised $150 million in its initial public offering on the Nasdaq. The SPAC, which currently has no merger target, aims to focus on healthcare and related industries....
BioPharma Dive
Deals•Jan 23, 2026
Terns Pharmaceuticals Secures Full Licensing Rights for Leukemia Drug TERN-701 From Hansoh Pharmaceutical
Terns Pharmaceuticals amended its licensing agreement with China's Hansoh Pharmaceutical, paying a $1 million upfront fee and a modest royalty to obtain the right to license TERN-701, its chronic myeloid leukemia candidate, in territories where Hansoh holds no rights. The...
BioPharma Dive
Deals•Jan 22, 2026
Mendra Therapeutics Raises $82M Series A to Accelerate Rare Disease Drug Development
Mendra Therapeutics, a new biotech founded by former BioMarin executives, announced an $82 million Series A financing led by OrbiMed, 8VC and 5AM Ventures. The capital will be used to acquire rare‑disease assets and accelerate development with AI. The funding was disclosed...
BioPharma Dive
Deals•Jan 22, 2026
Corxel Secures $287M Series D1 Funding to Advance Oral GLP-1 Obesity Pill
Corxel Pharmaceuticals announced a $287 million Series D1 financing round, with investors including SR One, TCGX, RA Capital Management, RTW Investments and Hengdian Group Capital. The capital will fund development of its oral GLP‑1 obesity drug CX11, licensed from China’s Vincentage, underscoring strong venture...
BioPharma Dive
Deals•Jan 9, 2026
Aurora Therapeutics Raises $16M Seed Round From Menlo Ventures
Aurora Therapeutics, a biotech startup co‑founded by Nobel laureate Jennifer Doudna and Fyodor Urnov, announced a $16 million seed round from Menlo Ventures to develop gene‑editing therapies for rare diseases under the FDA’s plausible mechanism pathway. The company will initially target...
BioPharma Dive
Deals•Jan 8, 2026
Parabilis Medicines Secures $305M Series F Funding Led by RA Capital, Fidelity Management, and Janus Henderson
Parabilis Medicines announced a $305 million Series F financing round, led by RA Capital Management, Fidelity Management, and Janus Henderson Investors. The capital will fund the development of its lead candidate zolucatetide, targeting the beta‑catenin pathway in cancer, and expand...
BioPharma Dive
Deals•Jan 8, 2026
EpiBiologics Raises $107M in Series B to Advance Protein-Degrading Cancer Drug
Biotech startup EpiBiologics announced a $107 million Series B financing to push its lead protein-degrading cancer therapy, EPI-326, into clinical trials. The round was co-led by GV and Johnson & Johnson’s corporate venture arm, with participation from Novartis Venture Fund,...
BioPharma Dive